Lodoz 5mg+6,25mg tablets film-coated

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

bisoprolol (bisoprolol fumarate), hydrochlorothiazide

Доступна с:

Merck KGaA

код АТС:

C07BB07

ИНН (Международная Имя):

bisoprolol (bisoprolol fumarate), hydrochlorothiazide

дозировка:

5mg+6,25mg

Фармацевтическая форма:

tablets film-coated

Штук в упаковке:

(30/3x10/) blisters

Тип рецепта:

Prescription

Статус Авторизация:

Registered

Дата Авторизация:

2015-05-04

Характеристики продукта

1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lodoz 2.5 mg/6.25 mg, film-coated tablet
Lodoz 5 mg/6.25 mg, film-coated tablet
Lodoz 10 mg/6.25 mg, film-coated tablet.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Lodoz 2.5 mg/6.25 mg, film-coated tablet:
Bisoprololfumarate 2.5 mg
Hydrochlorothiazide 6.25 mg
Lodoz 5 mg/6.25 mg, film-coatedtablet:
Bisoprololfumarate 5 mg
Hydrochlorothiazide 6.25 mg
Lodoz 10 mg/6.25 mg, film-coatedtablet:
Bisoprololfumarate 10 mg
Hydrochlorothiazide 6.25 mg
For the full list of excipients, see section 6.1.
_ _
_ _
3.
PHARMACEUTICAL FORM
Lodoz 2.5 mg/6.25 mg, film-coated tablet:
Film coated tablet
Yellow, round, biconvex upper side embossed heart, downside embossed
2.5.
Lodoz 5 mg/6.25 mg, film-coated tablet:
Film coated tablet
Pastel-pink, round, biconvex, upper side embossed heart, downside
embossed 5.
Lodoz 10 mg/6.25 mg, film-coated tablet:
Film-coated tablet
White, round, biconvex, upper side embossed heart, downsideembossed
10.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Mild to moderate essential hypertension.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
For individual therapy Lodoz is available in the strengths:
Lodoz 2.5/6.25 mg, film-coated tablets
Lodoz 5/6.25 mg, film-coated tablets
Lodoz 10/6.25 mg, film-coated tablets
_ _
The usual starting dose is one bisoprolol 2.5 mg / hydrochlorothiazide
6.25 mg tablet once daily.
3
If the antihypertensive effect of this dosage is inadequate, the dose
will be increased to one bisoprolol
5 mg / hydrochlorothiazide 6.25 mg tablet once daily and, if response
is still inadequate, to one
bisoprolol 10 mg / hydrochlorothiazide 6.25 mg tablet once daily.
If discontinuation is necessary, gradual discontinuation of bisoprolol
treatment is recommended, since
abrupt withdrawal of bisoprolol may lead to an acute deterioration of
the patient's condition, in
particular in patients with ischaemic heart disease.
_Patients with renal or hepatic impairment _
No dose adjustment is necessary in patients with mild-t